{"name":"CohBar, Inc.","slug":"cohbar-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CB4211 Dose 1","genericName":"CB4211 Dose 1","slug":"cb4211-dose-1","indication":"Other","status":"phase_1"},{"name":"CB4211 Dose TBD","genericName":"CB4211 Dose TBD","slug":"cb4211-dose-tbd","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"CB4211 Dose 1","genericName":"CB4211 Dose 1","slug":"cb4211-dose-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CB4211 Dose TBD","genericName":"CB4211 Dose TBD","slug":"cb4211-dose-tbd","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxONm1IZEZEaUh3dWZMNUdocWp1R3Fkc29TZFZsY25lZ3Uyb0R4LWZJa05VTUtncEJ0WjNERFR2VTVHNHN4YlZBVlV6VUpja1puX012UkZMSUo0OXBFQW5iYWl4NkxDdG5Lckt4VHBlSVB1UWZ1ZzV4VEJDdjQwTVluWHBsN3pwYjVsT0N0QnBmVm50Z3dh?oc=5","date":"2026-02-20","type":"pipeline","source":"Insightace Analytic","summary":"Anti-aging Therapeutics Market Size, Scope, Growth and Forecast to 2035 - Insightace Analytic","headline":"Anti-aging Therapeutics Market Size, Scope, Growth and Forecast to 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQRkR2bUhEemJ4dFRZSV9qNFZZWU85eUtzSHIxTDN5eVFVcjJHZzdCNmdNcDdINUlZUDNZZGdIeUxzZ3YxblFKdVFEY1hQcmJkSEVqQjNwWS1xQ2xpODlEUW15Wk1qWGM1bGRWdVVwZHNvLXBicm9Ic3o0T2FCUDZBQTl2UjhEQjBCcjgzbE9tenRINlZadkh3R2doYno1ZXIxeGhmcWM3MGZ1SnVobHpMYQ?oc=5","date":"2026-01-07","type":"deal","source":"Pharmaceutical Technology","summary":"Eli Lilly signs $1.3bn obesity-focused research deal with Nimbus - Pharmaceutical Technology","headline":"Eli Lilly signs $1.3bn obesity-focused research deal with Nimbus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxObGVfTXdwTW9zcDB0Z2g1eUNOWUtwVG5iQ3poalI2amRfT0hWaDh3VTVkN0RNU3BibDhFMHduNm90ckJhUktOeXY5SGFxR0U3MjFCTE5sTTJUYUZKSkxnZXR4NThUalZ1MHN6YUhFeHFTVVgyMTctOW9WR21QQWlxdGR5R010c01JWEo0TzlUdlNzTThkLXY1eFRockpDWU15bTdzOWdvdmE?oc=5","date":"2025-03-11","type":"deal","source":"Pharmaceutical Technology","summary":"Viking strikes $150m deal to secure supply of obesity drug - Pharmaceutical Technology","headline":"Viking strikes $150m deal to secure supply of obesity drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNcjFrQWhYaG1rTFM5VXFxQVg3YnYxQUJrQ1RSWmk4ZDk0aGE2R0xaVlVYdk91aDhmZy1lQXo5aUY0d0c0S0FpRDIxUzBOYXZUaFh2NnRuYlpaNXY1SWVIUzBpZmo4UjNlcGcwZUpWeEhZNGN4TjE2UGVpNzExMTZZY25VN0Z0VXdXMmd1SWE3cjlyc0dfOHptbThzUGQtSlRwMERvSQ?oc=5","date":"2023-09-22","type":"deal","source":"Bloomberg Law News","summary":"CohBar, Board Misled Investors on Morphogenesis Deal, Suit Says - Bloomberg Law News","headline":"CohBar, Board Misled Investors on Morphogenesis Deal, Suit Says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQNGxvcUhPTHhBeVFGZzZkUGwwOXlVYnk1bFRtUUgtaWw1X3FIYW4tLVRvUGcyaVVfS1gwdXlob1dOV1d1UDhMY3RBN2tNR2hMMWtzS2hnQmdTTFUycWxhZk5zZVBtTlVKSFhkVDlQczIzVml0eXdSQmh0eEYwb0dOYmFVSU1rNE1ESmRUdA?oc=5","date":"2023-06-21","type":"deal","source":"Pharmaceutical Technology","summary":"CohBar, Morphogenesis deal for immuno-oncology therapies - Pharmaceutical Technology","headline":"CohBar, Morphogenesis deal for immuno-oncology therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOU1FCWkppbG9nU05NZmFiLVVyTm1qaUo1bmplZDhfelRxVzZnZVFMajg5SVduWjRsbWxYRHNhY2p3cEU3UzNGV3VYem0wMTF4NExjQzgzZkV1clRmSFozTE5lZ2hNU2RESlVaNGh3UHQwRFF6MGg5cjFDNlc1WW9iN2RBNk4yYUs4?oc=5","date":"2023-05-23","type":"pipeline","source":"Yahoo Finance","summary":"CohBar Stock Doubles: Company Agrees To Merge With Morphogenesis To Advance Late-Stage Oncology Candidates - Yahoo Finance","headline":"CohBar Stock Doubles: Company Agrees To Merge With Morphogenesis To Advance Late-Stage Oncology Candidates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE94dmNmVDc1NDRSSThVRDdPRU1ieVRlOG12YkFUTXhfdkV5Uk9Xd1pHY08yeXZaN1VLZWFKZGt2WWM2RlhqT2pTYk05LWFhYXcyMzZRdUZSZU1KMW5sWWxuMExR?oc=5","date":"2022-11-28","type":"pipeline","source":"GuruFocus","summary":"Simon Allen Net Worth (2026) - GuruFocus","headline":"Simon Allen Net Worth (2026)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNby1HdVlrTW9UOGRiR0ZEVXFfLUtBT3pxS21NbnA4ZXRGd2l6a2doWDlYN0d6eVBncG9aZEdOVUI1ZG50dFdoN2haVXprMGJaTDg3WkU2S3FWZEVqdjEyY2NCN0w4SVRNUWZ2Q29fakVGZmk2M2lYZHBpRXI1dDlDaENmOFRNV28zemd1eUhKWjdjbzlacHFtb1lrTzMyRGFjbEZmZXJ6OUpZTmV2SnpUUDVUNUcwNlpqb0hGU0xSaU4wY0dGVmtqQURnZ2lqcGtQX2FEd0F3?oc=5","date":"2022-11-08","type":"pipeline","source":"Healio","summary":"Efruxifermin induces NASH resolution, improves fibrosis by at least 1 stage vs. placebo - Healio","headline":"Efruxifermin induces NASH resolution, improves fibrosis by at least 1 stage vs. placebo","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2019-12-09","type":"trial","source":"PBS","summary":"Health researchers disclose $188 million in conflicts of interest, NIH data suggests - PBS","headline":"Health researchers disclose $188 million in conflicts of interest, NIH data suggests","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQMTVIa1ZlRC1FRm5Uc01RZW9Jd2wyTHhHVnNoV0xJelpnOWhYZ3dsWHFrWVFsQVhxM0pBb2tKak1GQTJMdW9fLVIxWlFtSk5VRWo4cE1aTkJZbWE0ODhWV1pYWHZoNF9COXhxLU1wM2daRnRBbnNKUWEyd2dpTlhfNF9ubDUwZFdYUVFicFE3RmRoektIWXZlaC1xSEpYd9IBowFBVV95cUxNb0lma085bnVET1VIN05QTS1JVGs4NHIxXzQyNWdNREdWWTlXN21Ra1FyeGY2dFR1anRZY1RpUElDSUJraFJzV1F3WVdpemxzbWdYZ2U5Nm1TeFJXREJWQjA0SXNBTnZJNF8wOC1iNDBUdWRsdnIxdWJaZ2JjZXNkcTJKS0daZnVIdHRrTXgteW51dkY0TTFnVkZwMEN1MVg0MGpR?oc=5","date":"2018-10-01","type":"pipeline","source":"CBS News","summary":"SB 826: Nearly 100 California companies must add women to board of directors - CBS News","headline":"SB 826: Nearly 100 California companies must add women to board of directors","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}